Newsfeeds - Spark Newswire

3 minute read

FDA
News

Reported Late Monday March 06, BioMarin Provides Update On FDA Review Of ROCTAVIAN Gene Therapy For Adults With Severe Hemophilia A; FDA Extends PDUFA Target Action Date To June 30, 2023

Today, 7:56 AM

FDA Extends PDUFA Target Action Date to June 30, 2023 SAN RAFAEL, Calif., March 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global biotechnology company dedicated to transforming

BMRN

1 minute read

Why BioMarin Shares Are Plunging Today?

By Vandana Singh

Today, 7:56 AM

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.

BBIO

1 minute read

Wedbush Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $74

By Benzinga Newsdesk

Today, 7:56 AM

Wedbush analyst Andreas Argyrides maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $83 to $74.

BMRN

2 minute read

BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023

By Vandana Singh

Today, 7:56 AM

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported a break-even in Q4 FY22 compared to a loss of $(0.32) a year ago and the…

BMRN

1 minute read

Biomarin Pharmaceutical Q4 Sales $537.54M Beat $536.97M Estimate

By Benzinga Newsdesk

Today, 7:56 AM

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly sales of $537.54 million which beat the analyst consensus estimate of $536.97 million by 0.11 percent. This is a 19.50 percent increase over sales of $449.81

BMRN

1 minute read

BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst

By Vandana Singh

Today, 7:56 AM

BMO Capital Markets initiated coverage on BioMarin Pharmaceutical Inc (NASDAQ:BMRN) with a Market Perform rating and a price target of $107. Related: BioMarin’s…

BMRN

1 minute read

BMO Capital Initiates Coverage On Biomarin Pharmaceutical with Market Perform Rating, Announces Price Target of $107

By Benzinga Newsdesk

Today, 7:56 AM

BMO Capital analyst Kostas Biliouris initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Market Perform rating and announces Price Target of $107.

BMRN

1 minute read

Canaccord Genuity Initiates Coverage On Biomarin Pharmaceutical with Hold Rating, Announces Price Target of $119

By Benzinga Newsdesk

Today, 7:56 AM

Canaccord Genuity analyst Whitney Ijem initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold rating and announces Price Target of $119.

BMRN

1 minute read

Cramer Is Holding This Biotech Stock

By Lisa Levin

Today, 7:56 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN).

BMRN

1 minute read

BioMarin’s Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target

By Vandana Singh

Today, 7:56 AM

Wedbush has increased the price target on BioMarin Pharmaceutical Inc (NASDAQ:BMRN) from $74 to $84 while reiterating the Neutral rating. BioMarin reported three-year…

BMRN